Non-surgical treatment for kidney tumors using targeted radiation therapy
Official title: Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
Run by University Health Network, Toronto · NCT03747133 · Data updated 2026-11-12
This study is testing a new non-surgical radiation treatment for kidney tumors to see if it can help patients who can't have surgery feel better and improve their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | November 1, 2018 |
| Main results expected | November 2027 |
| Study ends | November 2027 |
| Registry record updated | June 4, 2026 |
| Trial ID | NCT03747133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with solid kidney masses that are inoperable due to high surgical risk or personal choice, and who have a performance status of 0-3.
✕Probably not a fit
Patients with multiple active metastases, end-stage renal failure, or certain hereditary syndromes will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of Stereotactic Ablative Radiosurgery (SABR) as a non-invasive treatment option for patients with renal tumors, particularly those who are not suitable candidates for surgery. The approach involves delivering high doses of radiation directly to the tumor while minimizing damage to surrounding healthy tissue. Patients will undergo assessments before and after treatment, with follow-up evaluations every four months for up to two years, during which they will complete quality of life questionnaires and receive standard imaging. The goal is to provide an effective alternative treatment for renal cell carcinoma, especially in older patients.
Why it matters
Potential benefit: If successful, this treatment could offer a viable non-surgical option for patients with renal tumors, improving their quality of life and treatment outcomes.
How similar studies have gone: Other studies have shown promising results with SABR for various tumors, indicating potential success for this approach in renal tumors as well.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm * Histological or radiological diagnosis of renal tumor * Inoperable: High risk for surgery or declined surgery * ECOG performance status of 0-3 Exclusion Criteria: * ≥5 active metastases * Systemic therapy (except endocrine therapy) within 60 days prior to SABR * Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney * Patients with end stage renal failure \> 4(KDOQI guidelines) * Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis
Where it's running
-
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Rachel Glicksman, MD — The Princess Margaret Cancer Foundation
- Study coordinator: Rachel Glicksman, MD
- Email: rachel.glicksman@uhn.ca
- Phone: 416-946-4501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRI-based AI to classify and grade renal tumors
This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.
-
Comparing robot-assisted kidney surgery in different positions
This study is testing if having kidney surgery with a robot while lying face down is better for recovery and results compared to the usual side position for patients with kidney tumors.
-
Using PET/MR to identify types of kidney tumors
This study is testing if a new type of imaging can help doctors tell the difference between aggressive and harmless kidney tumors in people with certain kidney masses.
-
3D image-guided robot-assisted surgery for complex kidney tumors
This study is testing a new robot-assisted surgery technique for complex kidney tumors to see if it leads to fewer complications and better long-term kidney function compared to the standard method.
-
Proton therapy for children with renal tumors
This study is testing a new type of proton therapy for children with kidney tumors to see if it can reduce side effects from treatment while still being effective.
-
Investigating the genetic causes of hereditary kidney cancer
This study is trying to find out the genetic causes of hereditary kidney cancer to help people with this condition and their families understand their risks and health better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.